November 12, 2019
Canadian drugmaker Intellipharmaceutics International Inc. has agreed to pay investors $1.6 million to settle a proposed class action alleging the company overstated opioid painkiller Rexista's ability to deter abuse before the U.S. Food and Drug Administration rejected its approval.
July 31, 2017
Intellipharmaceutics International Inc. allegedly lied to its investors about how sure it was its abuse-deterrent opioid painkiller Rexista actually prevented abuse when applying for U.S. Food and Drug Administration approval, a potential class told a New York federal court Friday.